Skip to main content
Springer Nature Link
Log in

Chronic HBV infection with persistently normal ALT b. not to treat

  • Others (Announcements, etc.)
  • Published:
Hepatology International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472–89.

    Article  PubMed  Google Scholar 

  2. Liaw YF, ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int. 2006;26:47–58.

    Article  Google Scholar 

  3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.

    Article  PubMed  CAS  Google Scholar 

  4. Dore G, Guan R, Jafri W, Sarin S. Management of chronic hepatitis B in challenging patient populations. Liver Int. 2006;26:38–46.

    Article  CAS  Google Scholar 

  5. Lin CL, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal alanine aminotransferase levels. Hepatology. 2007;45:1193–8.

    Article  PubMed  CAS  Google Scholar 

  6. Hsu HC, Wu MZ, Chang MH, Su IJ, Chen DS. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol. 1987;5:260–7.

    Article  PubMed  CAS  Google Scholar 

  7. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2:588–91.

    Article  PubMed  CAS  Google Scholar 

  8. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol. 1994;68:8102–10.

    PubMed  CAS  Google Scholar 

  9. Chu CM, Liaw YF. Natural history differences in perinatally versus adult-acquired disease. Curr Hepat Rep. 2004;3:123–31.

    Article  Google Scholar 

  10. Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomized controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet. 1988;2:298–302.

    Article  PubMed  CAS  Google Scholar 

  11. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United Sates. N Engl J Med. 1999;341:1256–63.

    Article  PubMed  CAS  Google Scholar 

  12. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 1999;30:770–4.

    Article  PubMed  CAS  Google Scholar 

  13. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36:186–94.

    Article  PubMed  CAS  Google Scholar 

  14. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol. 2003;38(Suppl 1):S90–S103.

    Article  PubMed  Google Scholar 

  15. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–95.

    Article  PubMed  CAS  Google Scholar 

  16. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biologic gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.

    Article  PubMed  CAS  Google Scholar 

  17. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.

    Article  PubMed  CAS  Google Scholar 

  18. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86.

    Article  PubMed  Google Scholar 

  19. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.

    Article  PubMed  CAS  Google Scholar 

  20. Yang PM, Chen DS, Lai MY, et al. Clinicopathologic studies of asymptomatic HBsAg carriers: with special emphasis on carriers older than 40 years. Hepatogastroenterology. 1987;34:251–4.

    PubMed  CAS  Google Scholar 

  21. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal aminotransferase levels. Am J Med. 2004;116:829–34.

    Article  PubMed  CAS  Google Scholar 

  22. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognosis and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat. 2007;14:147–52.

    Article  PubMed  Google Scholar 

  23. Kim HC, Nam CM, Jee S H, Han K H, Oh D K, Su-h I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983.

    Article  PubMed  CAS  Google Scholar 

  24. Park BK, Park YN, Ahn SH, Lee KS, Chon CY, Moon YM, et al. Long-term outcome of chronic hepatitis B based on histologic grade and stage. J Gastroenterol Hepatol. 2007;22:383–8.

    Article  PubMed  CAS  Google Scholar 

  25. Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46:395–401.

    Article  PubMed  Google Scholar 

  26. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.

    Article  PubMed  CAS  Google Scholar 

  27. Gish R, Chang TT, de Man R, Gadano A, Sollano J, Han KH, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) Chronic hepatitis B patients (Study ETV-022) Hepatology. 2005;42(Suppl):267A.

    Google Scholar 

  28. Lok A, Schiff E, Tsai SL, Rustsgi VK, Schiffman M, Martin P, et al. Entecavir is effective irrespective of Baseline ALT and HBV DNA Strata for Histological and Virological Endpoints. Gastroenterology. 2005;128:742.

    Article  Google Scholar 

  29. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528–36.

    PubMed  CAS  Google Scholar 

  30. Lai CL, Gane E, Chao-Wei H, Thongsawat S, Wang Y, Chen Y, et al. Two-Year results from the Globe Trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Hepatology. 2006;44(Suppl):222A.

    Google Scholar 

  31. Yoo BC, Kim H, Lee KS, Kim TH, Paik SW, Ryu SH, et al. A 24-week clevudine monotherapy produced profound on-treatment viral suppression as as sustained viral suppression and normalization of aminotransferase levels for 24 weeks off-treatment in HBEAg(+) chronic hepatitis B patients. Hepatology. 2007;45:1172–8.

    Article  PubMed  CAS  Google Scholar 

  32. Yoo BC, Koh KC, Chung YH, Han BH, Byun KS, Um S, et al. Clevudine is highly efficacious in HBEAg(-) chronic Hepatits B patients with a sustained antiviral effect after cessation of therapy. Hepatology. 2007;46:1041–8.

    Article  PubMed  CAS  Google Scholar 

  33. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19:1276–82.

    Article  PubMed  CAS  Google Scholar 

  34. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis. 2005;25:9–19.

    Article  PubMed  CAS  Google Scholar 

  35. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385–91.

    Article  PubMed  CAS  Google Scholar 

  36. Colonno R, Rose R, Levine S, Baldick J, Pokornowski Plym M, et al. Entecavir two years resistance update: no resistance observed in nucleoside naïve patients and low frequency resistance emergence in lamivudine refractory patients [Abstract]. Hepatology. 2005;42(Suppl 1):573A.

    Google Scholar 

  37. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006;101:2076–89.

    Article  PubMed  Google Scholar 

  38. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effective analysis. Ann Intern Med. 2005;142:821–31.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Yonsei University College of Medicine, Liver Cirrhosis Clinical Research Center, Seoul, Korea

    Kwang-Hyub Han & Do Young Kim

Authors
  1. Kwang-Hyub Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Do Young Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kwang-Hyub Han.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, KH., Kim, D.Y. Chronic HBV infection with persistently normal ALT b. not to treat. Hepatol Int 2, 185–189 (2008). https://doi.org/10.1007/s12072-008-9068-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-008-9068-z

Search

Navigation